|
|
QLT Inc. - Earning & Dividend Analysis Snapshot
This detailed Report provides an Earnings and Dividends history for QLT Inc.. Tabular results include up to a ten-year history of "as reported" Earnings per Share and Dividends per Share plus a calculation of the amount of earnings paid out over the year in dividends (i.e. Payout Ratio). Earnings and Dividends are presented on both a Quarterly and Annual basis. An annual Percent Change factor is calculated for both Earnings and Dividends.
QLT Inc.. The Group's principal activities are to discover, develop, manufacture and commercialise therapeutics for human health care including eye diseases, cancer and dermatological conditions. The products include visudyne, eligard, punctal plug and lemuteporfin. The eligard line of products are used for treatment of prostate cancer. Visudyne has been approved in over 75 countries and eligard is approved in over 60 countries. The Group's products are sold in the United States, Europe, Canada and other countries. On 18-Oct-2007 the Group acquired ForSight Newco II Inc, now known as QLT Plug Delivery Inc.
Not the Report you are looking for? Click here for more browsing options.
Layout and Content of a Typical Report
|
|
|
|
|